ViroGates

ViroGates develops biomarker technology based on suPAR (soluble urokinase Plasminogen Activator Receptor), a biomarker of chronic inflammation that predicts patient outcomes before symptoms appear. The company's suPARnostic product line includes TurbiLatex for high-throughput CE-IVD approved testing on existing automated lab systems, ELISA for batch processing as the gold standard in suPAR testing, and Quick Triage for rapid 20-minute results in emergency settings. Higher suPAR levels are linked to greater risk of cancer, diabetes, cardiovascular disease, and organ failure, while lower levels indicate good underlying health. Founded in 2001 and headquartered in Copenhagen, Denmark, the company has raised approximately $28.4M in Series B funding. ViroGates differentiates itself through suPAR's unique ability to measure chronic inflammatory burden associated with aging and biological age, serving clinical diagnostics for emergency departments and acute care, as well as longevity clinics for preventive health management.